Innovaderm is proud of its partnership with Nimbus Therapeutics for an investigational oral TYK2 inhibitor, in a Phase 2b trial for patients with moderate-to-severe psoriasis. Innovaderm’s reputed teams once again proved their expertise throughout the whole project, from the study design all the way to the trial reports, under tight timelines. “There are many CRO […]
[MONTREAL, QUEBEC — December 19, 2023] Allergy recently published RAPT Therapeutics’ phase 1a/1b atopic dermatitis (AD) study, in which Innovaderm Research was a key partner, serving as the contract research organization (CRO). This was a first-in-human and proof of concept randomized, placebo-controlled Phase 1a/1b monotherapy study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and CCR4 […]
Click here for a PDF version of this case study Outcomes Innovaderm successfully transitioned this rescue study from another CRO and this resulted in: More than doubled patient enrollment in 1 month Started enrollment 1 month faster than initial projection All 5 newly added sites were actively recruiting Study Characteristics Study Phase: IIa Study […]
Click here for a PDF version of this case study Outcomes Innovaderm successfully managed this HS study and this resulted in: Enrollment completed 3 months ahead of schedule Study Characteristics Study Phase: II Patient Population: Hidradenitis Suppurativa IP Route of Administration: Systemic - Subcutaneous Site distribution: 25 in North America and 16 in Europe […]
Click here for a PDF version of this case study Outcomes Innovaderm successfully managed this PPP study and this resulted in: Enrollment completed 3 weeks ahead of schedule; Successful study and satisfied sponsor Study Characteristics Study Phase: II Patient Population: Palmoplantar pustulosis IP Route of Administration: Systemic Sites Distribution: 17 sites in 2 countries […]
Click here for a PDF version of this case study Study Characteristics Study Phase: II Patient Population: 126 patients with Notalgia Paresthetica (NP) (Pruritus associated with NP) IP Route of Administration: Systemic (oral) Site Distribution: 33 sites (USA and Canada) Study Procedures: Photographs, Pharmacokinetics, Electrocardiograms Study Challenges Patient awareness: Challenge in advertisement as […]
Click here for a PDF version of this case study Outcomes Innovaderm’s outstanding support on this alopecia areata study resulted in a rapid increase in enrollment rates and the successful management of this trial Study Characteristics Study Phase: II Patient Population: Alopecia Areata IP Route of Administration: Systemic Sites distribution: 12 sites (CAD-USA) Complex […]
Click here for a PDF version of this case study Outcomes Innovaderm successfully managed this AD study and this resulted in: Enrollment completed 2 months earlier than planned; Innovaderm CRU recruited 33% of patients Study Characteristics Study Phase: Ib Patient Population: 36 subjects with moderate to severe AD IP Route of Administration: Systemic - […]
Click here for a PDF version of this case study Outcomes Innovaderm successfully managed this acne study and this resulted in: Enrollment completed 1 month earlier than planned Study Characteristics Study Phase: II Patient Population: Acne vulgaris (enrolling pediatrics & adults) IP Route of Administration: Systemic Sites distribution: 15 sites (USA) Study […]
Click here for a PDF version of this case study Outcomes Innovaderm successfully transitioned this rescue study from another CRO and this resulted in: Increase in enrollment of over 10x Tripled site performance post transition On-time patient recruitment Study Characteristics Study Phase: II Study Status: Rescue study Patient Population: Palmoplantar pustulosis (PPP) IP Route […]